Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Jame Abraham, MD, FACP

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Breast Cancer

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.

Breast Cancer

Harold J Burstein MD PhD and Lisa A Carey MD

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

The TNT trial comparing docetaxel to carboplatin
The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
Pembrolizumab in a phase Ib study

May

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults

Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer